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SAMMANFATTNING
Bakgrund
Hjärtsvikt är en vanlig sjukdom som medför sänkt livskvalitet och stor risk för död. Idag delas 
hjärtsvikt in i tre typer baserat på andelen blod som pumpas ur vänster kammare vid varje hjärtslag: 
Hjärtsvikt med bevarad (HFpEF), måttligt sänkt (HFmrEF) och sänkt ejektionsfraktion (HFrEF). 
Kunskap om hur vi ska behandla patienter med HFpEF och i vilken utsträckning HFpEF och HFrEF 
skiljer sig åt saknas fortfarande i stor utsträckning. På samma sätt är också kunskapen om eventuella 
könsskillnader vid hjärtsvikt bristfällig, trots att hälften av patienterna är kvinnor. 
Syfte
Att undersöka
(1) om den hämning av tillväxthormonaxeln som finns hos patienter med HFrEF även förekom-
mer hos patienter med HFpEF. 
(2) nivåer och betydelse av de fetmarelaterade peptiderna leptin och adiponectin hos patienter 
med HFpEF och HFrEF. 
(3) potentiella könsskillnader i livskvalitet hos patienter med HFpEF. 
(4) potentiella könsskillnader i nivåer av och prognostisk betydelse av  hjärtsviktshormonet N-
terminal pro natriuretisk peptid typ B (NT-proBNP) vid kronisk hjärtsvikt 
Resultat 
Hämning av tillväxtfaktorhormonaxeln
Vid analys av Insulin-like growth factor 1 (IGF-1) och dess bindarprotein (IGFBP-1) fann vi att både 
HFpEF och HFrEF uppvisade en hämning av tillväxtfaktorhormonaxeln mätt som förhöjda nivåer 
av IGFBP-1. Förhöjda nivåer av IGFBP-1 var också associerade med förhöjt NT-proBNP eller grad 
av hjärtsvikt. Emellertid verkade hämningen av tillväxtfaktorhormonaxeln vara mer uttalad i HFrEF 
och sänkta nivåer av IGF-1 var associerade med sämre prognos enbart hos patienter med HFrEF. 
Fetmarelaterade leptin och adiponectin 
Vid analys av leptin och adiponectin fann vi förhöjda nivåer av dessa i både HFpEF och HFrEF. 
Emellertid uppvisade endast HFrEF den så kallade fetmaparadoxen, d.v.s. att förhöjda nivåer av 
leptin är associerade med bättre prognos. Fynden talar för att HFpEF har en mer konventionell 
riskprofil avseende leptin och fetma.
Livskvalitet hos kvinnor och män med HFpEF
Vi fann att både kvinnor och män med HFpEF har sänkt livskvalitet. Kvinnorna rapporterade dock 
sämre generell livskvalitet och associationen mellan livskvalitet och grad av hjärtsvikt var svagare 
hos kvinnor. En koppling mellan sänkt livskvalitet och sämre prognos fanns endast hos män. 
Fynden talar för att sänkt livskvalitet hos kvinnor i stor utsträckning förklaras av andra faktorer än 
hjärtsvikten i sig vilket bör beaktas i eftersträvan att förbättra patienternas livskvalitet. 
Betydelse av kön för nivåer av svikthormon vid olika hjärtsviktstyper
Nivåer av svikthormonet NT-proBNP var högre hos kvinnor än hos män i alla de undersökta 
hjärtsviktstyperna. Faktorer relaterade till nivåer av NT-proBNP och associationen mellan 
förhöjda nivåer och prognos var emellertid likartade. Detta stödjer att NT-proBNP kan användas 
för prognostisering av hjärtsvikt oaktat kön, men betydelsen av de relativt stora könsskillnaderna i 
nivåer hos patienter med HFpEF och låga NT-proBNP nivåer behöver utvärderas.
Slutsats
HFpEF och HFrEF uppvisar väsentliga likheter och skillnader relaterade till metabolism, 
hormonnivåer och kön. Betydelsen av detta avseende sjukdomsutveckling och eventuell behandling 
återstår att undersöka. 
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ABSTRACT
Background
Heart failure (HF) is common and associated with impaired quality of life (QoL) and poor prognosis. 
There is a ternary classification of HF based on ejection fraction (EF): HF with preserved(HFpEF), 
mid-range EF(HFmrEF), and reduced EF(HFrEF). How to treat the syndrome of HFpEF, and the 
extent to which HFpEF and HFrEF are similar, still remain elusive. Likewise, despite the fact that 
half of the patients with HF are women, the role of sex in HF is often overlooked. 
Aims
(1) To investigate whether HFpEF and HFrEF share features of anabolic impairment regarding 
insulin-like growth factor 1 (IGF-1) and IGF binding protein-1 (IGFBP-1).
(2) To assess levels of the obesity related peptides, leptin and adiponectin, and whether the 
obesity paradox exists in HFpEF.
(3) To investigate potential sex-specific differences in QoL in HFpEF.
(4) To assess the impact of sex on N-terminal B-type natriuretic peptide (NT-proBNP) in chronic 
HF across the EF spectrum.
Results
The IGF-1 axis in HFpEF and HFrEF
Serum IGF-1and IGFBP-1 concentrations and their associations with other biomarkers and outcomes 
were analysed in patients with HFpEF and HFrEF. IGF-1 concentrations were lower and associated 
with poor prognosis in HFrEF only. However, IGFBP-1 was increased and associated with NT-
proBNP in both HF phenotypes. This suggests inhibition of the IGF-1-axis in both syndromes and a 
possible mechanistic link between IGFBP-1 and natriuretic peptides in HF.
Leptin and adiponectin in HFpEF and HFrEF
Serum leptin and adiponectin concentrations and their associations with other biomarkers and 
outcomes in patients with HFpEF and HFrEF were analysed. Our findings indicate that the two HF 
phenotypes share elevated levels of leptin and adiponectin. The obesity paradox regarding leptin, 
with higher levels being associated with better outcome was nevertheless only demonstrated in 
HFrEF, pointing towards a more conventional metabolic profile in HFpEF. 
Sex and quality of life in HFpEF
We assessed QoL in HFpEF through generic and HF specific QoL instruments. Women with HFpEF 
express worse global QoL than men. Overall, QoL was only weakly associated with measures of HF 
severity and the associations were weaker in women. In men only, poor QoL was associated with 
worse outcome. Overall, this suggests, that in order to improve QoL in HFpEF patients, in particular 
in women, other factors than HF must be addressed. 
Impact of sex on NT-proBNP across HF phenotypes
We analysed concentrations of NT-proBNP, and associations with clinical characteristics and 
outcomes in the three HF phenotypes, by sex. Women with chronic HF across the entire EF spectrum 
have higher NT-proBNP concentrations than men. However, associations between NT-proBNP 
concentrations and clinical characteristics as well as outcomes are largely similar. This supports 
the current use of NT-proBNP for prognostic purposes across HF phenotypes but the impact of sex-
differences in the lower NT-proBNP range warrants further investigation. 
Conclusion
HFpEF and HFrEF display important similarities and differences related to metabolic biomarkers, 
natriuretic peptides, and sex. The impact of these factors on the pathogenesis of and in manifest HF, 
and as potential therapeutic targets warrants further investigation. 
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ABBREVIATIONS
BMI body mass index 
BNP B-type natriuretic peptide
CAD coronary artery disease 
CI confidence interval
cGMP cyclic guanosine mono phosphate 
EF left ventricular ejection fraction
eGFR estimated glomerular filtration rate 
ESC European Society of Cardiology 
EQ-5D EuroQoL 5 dimensions 
EQ-VAS EuroQoL visual analogue scale 
HF heart failure
GH growth hormone
HFmrEF heart failure with reduced ejection fraction
HFpEF heart failure with preserved ejection fraction
HFrEF heart failure with mid-range ejection fraction
HOMA-IR homeostatic model assessment-insulin resistance
HR hazard ratio
IGF-1 insulin-like growth factor 1
IGFBP-1 insulin-like growth factor binding protein 1
IHD ischemic heart disease
KaRen Karolinska-Rennes
KCCQ Kansas City Cardiomyopathy Questionnaire
ln natural logarithm
LV left ventricular
NT-proBNP N-terminal pro B-type natriuretic peptide
NO nitric oxide
NP natriuretic peptide
MLHFQ Minnesota Living With Heart Failure Questionnaire
NYHA New York Heart Association 
OR odds ratio
PRO patient reported outcome
RAAS renin-angiotensin-aldosterone system
ROS reactive oxygen species 
SBP systolic blood pressure
SD standard deviation
SGLT-2  sodium-glucose co-transporter-2
SNS sympathetic nervous system 
T2DM diabetes type 2
QoL quality of life
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INTRODUCTION
Heart failure (HF) is a common syndrome and affecting 2% of the Western population, 10% 
above the age of 65 and up to 20% above 75 years1. World-wide, more than 26 million 
people are living with HF and it is associated with poor quality (QoL) of life as well as 
high morbidity and mortality2. The global, overall, annual cost of HF has been estimated to 
$108 billon3, but is expected to triple between 2010 and 2030 due to increased prevalence of 
sedentary life style and aging of the population4. 
Despite decades of success-stories in HF-therapy with neurohormonal antagonists, use of 
devices, and lately enhancement of adaptive hormonal pathways5, there is still no evidence 
based therapy for almost half of the patients suffering from HF. Considering the global 
burden of the disease, there is an urgent need to expand the understanding of the syndrome, 
to find new treatment targets, and to develop therapies improving not only survival, but also 
patient reported outcome (PRO)6. 
About half of the patients living with HF are women. The risk of developing HF, the 
phenotypic expression of the HF syndrome, outcome and response to therapy are different 
in men and women7. Furthermore, diseases associated with HF, such as obesity, diabetes, 
and hypertension are known to affect women and men differently8. Women are still 
underrepresented in clinical trials and both preclinical and clinical research are still mainly 
performed in males or without sex-specific analyses9. 
Against this background, with the overall aim of improving the understanding of heterogeneous 
syndrome of HF, this thesis addresses biomarkers related to HF, PRO, and the role of sex 
across the ejection fraction (EF) spectrum. 
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Definition of heart failure and role of ejection fraction 
According to the definition by the European Society of Cardiology (ESC), HF is “a 
clinical syndrome characterized by typical symptoms (e.g. breathlessness, ankle swelling 
and fatigue) that may be accompanied by signs (e.g. elevated jugular venous pressure, 
pulmonary crackles and peripheral edema) caused by a structural and/or functional cardiac 
abnormality, resulting in a reduced cardiac output and/or elevated intracardiac pressures 
at rest or during stress”10. Physiologically this means that the heart is unable to meet the 
metabolic demands at rest or during exercise, or that the metabolic requirements are met only 
through increased filling pressures. 
Normal filling of the heart in diastole and adequate ejection of blood in systole are essential for 
cardiac performance. Thus both diastolic and systolic function as well as vascular compliance 
must be maintained for a normal cardiac function. However, HF research and therapy have for 
long focused on systolic dysfunction, partly due to the widespread use of low left ventricular 
(LV) EF for diagnosing HF in clinical practice. When studies in the early 2000 demonstrated a 
bimodal distribution of EF among HF patients11,12, the paradigm of using EF to categorize HF 
evolved. In 2016, the ESC guidelines on HF proposed a ternary classification of chronic HF: 
HF with preserved (HFpEF), mid-range (HFmrEF), and reduced EF (HFrEF), characterized by 
EF≥50%, 40-49%, and <40% respectively. Apart from signs and symptoms of HF and EF, the 
diagnosis of HFmrEF and HFpEF also requires elevated natriuretic peptides (NPs) and relevant 
structural or functional heart disease such as LV hypertrophy, left atrial enlargement, and/or 
diastolic dysfunction. Since diastolic dysfunction can exist throughout the EF spectrum, and 
since systolic function is not necessarily normal in HFpEF, the old nomenclature of systolic and 
diastolic HF is no longer used10.
Depending on cohort analyzed, about half of the HF patients have HFrEF, and the remaining 
HFmrEF or HFpEF11,13,14, Figure 1. 
BACKGROUND
Figure 1. Schematic overview of diagnostic criteria and characteristics of the three EF phenotypes. 
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HFpEF and HFrEF- one disease or two?
It has been debated whether HFpEF is indeed the same disease as HFrEF with different EF, 
or whether the two, despite similar symptoms and signs, are actually pathophysiologically 
different. The prevailing view is that in HFrEF an initial injury (index event), e.g. myocardial 
infarction, leads to loss of myocardial function. This in turn triggers maladaptive neuro-
hormonal activation, myocardial remodeling including LV dilatation, and eccentric 
hypertrophy leading to manifest HF. In contrast, in HFpEF a comorbidity driven inflammatory 
state leads to endothelial damage and microvascular dysfunction through decreased nitric 
oxide (NO) and cyclic guanosine monophosphate (cGMP), Figure 2. Ultimately this results 
in concentric LV remodeling and reduced myocardial compliance. The bimodal distribution of 
EF, the lack of benefit in HFpEF of the neurohormonal antagonists, and different macroscopic 
and myocellular patterns of LV remodeling support this paradigm. Furthermore, the disease 
progression, comorbidity profile, and the sex-distribution are different in HFpEF compared 
with HFrEF11,15. 
The introduction of HFmrEF to the European HF guidelines in 2016 was made to dichotomize 
between “true” HFrEF or HFpEF and the “grey or mixed area” between these syndromes. 
This is considered important in terms of etiology, demographics, co-morbidities, response to 
therapies, and design of interventional trials10.   
HFrEF- pathophysiology, risk factors, clinical characteristics, and treatment
As described, HFrEF is caused by a direct injury or disease state affecting the myocardium, 
leading to reduced LV contractility. About 2/3 of HFrEF cases are caused by ischemic heart 
disease (IHD). Other primarily cardiac aetiologies include cardiomyopathies, myocarditis, 
Figure 2. Overview of the pathogenesis in HFpEF and HFrEF. EndMT, endothelial mesenchymal 
transition. Heart, Lam CSP, Lund LH, 2016, reproduced with permission from the publisher. 
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and valvular diseases. Extra-cardiac causes of HFrEF are abundant, including endocrine 
disorders, systemic inflammatory diseases, alcohol- or drug-abuse, or toxic reactions. 
Important risk factors are IHD, diabetes, smoking, and hypertension16. 
The initial myocardial injury reduces cardiac output, which leads to compensatory 
neurohormonal activation to preserve oxygen delivery. These mechanisms include activation 
of the sympathetic nervous system (SNS) and the renin-angiotensin-aldosterone system 
(RAAS). While these mechanisms initially are adaptive, they become maladaptive in 
long term, leading to cardiac remodeling with eccentric hypertrophy, LV dilatation, and 
cardiomyocyte dysfunction. This will further reduce cardiac output, and creates the vicious 
circle of worsening HF. The basis of HF therapy involves inhibiting these neurohormonal 
pathways with β-blockers and RAAS-inhibitors. Moreover, adaptive responses in HF can 
also be targeted, such as with the inhibition of the enzyme neprilysin, that increases the 
bioavailability of presumably cardioprotective NPs10,17. 
HFpEF- pathophysiology
HFpEF is characterized by multiple impairments in ventricular diastolic and systolic 
function, vascular function, and reserve capacity18. The pathophysiological hypothesis is 
that common non-cardiac diseases, such as hypertension, obesity, diabetes type 2 (T2DM), 
anemia, pulmonary disease, or chronic kidney disease induce a pro-inflammatory state. This 
leads to endothelial dysfunction,  microvascular inflammation, recruitment of immune cells, 
reactive oxygen species (ROS), and lower bioavailability of NO resulting in microvascular 
dysfunction and cardiac remodeling15,19,20. The pluricellularity of the heart and the important 
role of other cell-types than cardiomyocytes, such as endothelial cells, immune cells, 
cardiac stem cells, and fibroblasts are recognized. In particular, the role of the microvascular 
endothelial cells is stressed, both as a sensor of the local environment in the heart and in the 
bloodstream and as an effector in endothelium derived signaling, affecting adjacent cells. 
Apart from NO, a plethora of small molecules, peptides, and proteins such as prostacyclin, 
angiotensin-II, endothelin, growth-factors, and inflammatory cytokines are involved in this 
complex cellular crosstalk21.
The diastolic dysfunction in HFpEF is linked to both myocyte hypertrophy and passive 
stiffness due to fibrosis and phosphorylation of titin, as well as impaired active relaxation15,22-24. 
HFpEF- risk factors, clinical characteristics, and treatment
Patients with HFpEF tend to be older and to have a higher prevalence of obesity, hypertension, 
and atrial fibrillation compared with patients with HFrEF14,16,25. The aging population and the 
increase in prevalence of comorbidities are leading to a growth in prevalence of HFpEF by 
10% per decade18. 
In contrast to HFrEF, there is a female predominance in HFpEF26 and there seem to be sex 
specific traits in cardiac structure and function making women more prone to develop HFpEF 
with aging. Arterial stiffening is greater in women and women appear more disposed to 
develop concentric LV remodeling with pressure overload8,27. In HFpEF, diastolic impairment 
is also more pronounced in women28. 
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There is currently no evidenced based therapy for patients with HFpEF. Contrary to 
expectations, conventional neuro-hormonal antagonists, like β-blockers and RAAS-blockade 
have not been convincingly efficient29-32. Numerous novel interventions, such as sildenafil, 
organic or inorganic nitrates, and soluble guanylate cyclase stimulators have been studied 
but have generally failed or not yet been convincingly proven efficient33. Reasons for the 
lack of success might be the heterogeneity of HFpEF and the failure to match treatment 
with phenotype, disease stage, and severity6,34-37. Furthermore, only a minority of patients 
presenting to hospitals and clinics are actual candidates for interventional trials with strict 
selection criteria, there is also a concern about the generalizability of trial results36. As such, 
HFpEF is considered one of the major challenges in contemporary cardiology38.
HFmrEF
The middle HF phenotype, HFmrEF was introduced not because of a suspicion of it being 
a pathophysiologically unique HF phenotype, but rather due to the heterogeneity of the 
group, the possible transition of patients from one EF category to another,  the imprecise EF 
measure, and to stimulate and refine research10,39,40. Between 13 and 24% percent of patients 
in population based studies of HF have HFmrEF. On group level, HFmrEF seem to be in 
between HFpEF and HFrEF regarding age-, sex- and comorbidity-profile, with the important 
exception of IHD, regarding which HFmrEF is more similar to HFrEF14,41-44. In post-hoc 
analyses, patients with HFmrEF also seem to respond to conventional HF therapy in a similar 
way as HFrEF45,46.
Prognosis in heart failure 
HF is associated with high mortality. The prognosis in HFpEF is appears to be slightly better 
than in HFrEF25. Similar prognosis across the EF spectrum has been reported from the American 
Get With the Guidelines registry with a one-year mortality of 37,5 vs, 35.1 vs 35.6% after acute 
HF hospitalization in HFrEF, HFmrEF, and HFpEF respectively. Hospital readmission rates 
were nevertheless higher in HFrEF and HFmrEF vs. HFpEF; 30.9 and 28.4 vs. 24.3 % 47. In 
chronic HF, 1-year mortality in Europe was higher in HFrEF (8.8%) vs. HFpEF (6.3%), with 
HFmrEF intermediate (7.6%)44. In a Swedish cohort of a mix of in- and outpatients, crude 1- 
year mortality was 15% in HFrEF, 14% in HFmrEF, and 17% in HFpEF14. 
Patient reported outcomes
While focus in interventions in HF, in particular clinical trials, for long has been on reducing 
“hard endpoints”, like mortality or rehospitalization, a holistic approach to HF care, including 
patient satisfaction and PRO is now emphasized48. The Food and Drug Administration even 
stresses the use of PRO as a clinical trial endpoint49. 
It is well established that patients with HFrEF experience impaired QoL, and women with 
HFrEF report lower QoL than men7,50. As in HFrEF, QoL is impaired in HFpEF and has been 
associated with poor prognosis50-53. There is a substantial variability in QoL, independent of 
HF severity, and impaired QoL in patients with HF appears largely explained by other factors 
         Heart failure: Biomarkers, ejection fraction, and sex
15
than HF itself52,54. Furthermore, while poor QoL is associated with poor outcomes, improved 
QoL in the trial setting is often linked to better outcome55.
There are several instruments for assessment of QoL, both HF-specific focusing on disease 
specific impairments, and generic instruments. Disease specific instruments may be preferred 
to generic when assessing specific treatment effects. Generic instruments provide a broader 
assessment of QoL, rather than the impact of a particular disease56. The most highly ranked 
and commonly used HF specific instruments are Kansas City Cardiomyopathy Questionnaire 
(KCCQ), Minnesota Living with Heart Failure Questionnaire (MLHFQ), and Chronic Heart 
Failure Questionnaire57. All three have a good reliability (internal consistency, test-retest 
reliability, and interrater reliability) and validity. The choice of instrument depends rather 
on the setting in which they are used, since for example their qualities regarding forms of 
administration (KCCQ and MLHFQ can be self-administered) and sensitivity to change 
differ (KCCQ and Chronic Heart Failure Questionnaire are superior to MLHFQ)57. 
Commonly used generic QoL instruments are Short-Form 36 Health Survey, the Sickness 
Impact Profile, and the EuroQoL 5D (EQ-5D)56.
Role of sex
Half of the patients living with HF are women and the prevalence of HF in adults in the 
United States between 2011-2014 was 2.4% in men vs. 2.6% in women1.  While women are 
diagnosed with HF later in life, the overall lifetime risk is about 20% in both sexes7. Both in 
HFrEF and HFpEF/HFmrEF, prognosis is better for women, despite lower QoL and greater 
functional impairment in women7,25,58,59.
While men are overrepresented in HFrEF, women are more likely to develop HFpEF26. Sex-
specific differences in cardiac structure and function and the loss of protective estrogen 
after menopause are possible explanations27. As mentioned, ventricular arterial stiffening is 
greater in women and women more likely develop concentric LV remodeling with pressure 
overload8,27. The diastolic dysfunction is also more pronounced in women with HFpEF28. 
Furthermore, comorbidities related to HF seem to affect women and men differently and 
women with diabetes or hypertension have a higher risk of developing HF than men8,60. 
Autoimmune diseases and iron-deficiency, that are related to HF and inflammation, are also 
more common among women. In addition, pregnancy related disorders like preeclampsia are 
evidently unique for women8, Figure 3. 
The evidence-based treatment for HFrEF is largely based on trials where women have been 
underrepresented with a fraction of women below 30%7,61. In HFpEF, evidence based therapy 
is lacking, but despite the high prevalence of HFpEF among women, women are often 
excluded from trials, likely due to higher age or comorbidity burden61,62. When hospitalized 
for HF, women are equally likely to receive diuretics, but less likely to be treated with 
vasoactive therapy and evidence-based oral therapy63. 
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Natriuretic peptides
The NP family includes a large number of peptides and peptide fragments, e.g. A-type NP, 
B-type natriuretic peptide (BNP), and C-type NP64. While they all seem to contribute to the 
adaptive neurohormonal system in HF, the most well-known and clinically used is BNP, or 
the cleaving fragment of the pro-hormone, N-terminal-proBNP(NT-proBNP)65,66. 
In the healthy state, BNP is mainly secreted in the atria, whereas with increased ventricular 
wall stress in HF, secretion is shifted to the ventricle. BNP acts through the NP-receptor A, a 
guanylate-cyclase receptor, and activation leads to increased formation of cyclic guanosine 
mono-phosphate (cGMP). The actions of BNP counteracts the activation of the RAAS and 
SNS by causing vasodilation, natriuresis, and opposing adverse remodeling64,67. NT-proBNP 
is produced in equimolar amounts as BNP, but exists in higher plasma concentrations due to 
longer half-life. The biologic role of NT-proBNP, if any, is not known. However, due to a 
longer half-life and stability in vitro, NT-proBNP is widely used instead of BNP to measure 
BNP activity67. 
Figure 3. The influence of comorbidities in the pathogenesis of HFpEF in women. Beale et al., 
Circulation, 2018. Reproduced with permission from the journal. 
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The use of NPs is well established for diagnostic10,68-70 and prognostic13,71-73 purposes in 
HF. NPs are also used for trial selection purposes and as surrogate outcomes in both acute 
and chronic HF trials, although the latter has not convincingly been shown to translate into 
better outcomes74. Considering their adaptive effects in HF, they are used and investigated as 
treatment targets17,64 and for guidance of therapy43,75-77.
Low NPs are considered to have a strong negative predictive value in excluding HF10, although 
normal BNP is indeed found in patients with HFpEF despite increased filling pressures78. 
Levels of BNP/NT-proBNP are higher in HFrEF compared to HFmrEF and HFpEF79. High 
levels are associated with severity of HF and poor prognosis in both the acute and chronic 
setting across all EF phenotypes79-81. 
Females, both healthy and with acute decompensated HF, have higher NP concentrations than 
men, which may at least partially be explained by sex-hormones, i.e. higher oestrogen levels 82-85. 
Nevertheless, despite higher concentrations in females with acute HF, the short term prognostic 
ability of BNP is similar in both sexes across the EF spectrum13. In contrast, in chronic HF 
higher86, similar28, and lower 59 NT-proBNP concentrations are reported in females vs. males. 
Likewise regarding long term prognosis, data is diverging and a mix of EF phenotypes limits 
the interpretation87-89.  In chronic HF, population based studies are lacking but in the trial setting 
of mixed HFpEF/HFmrEF, data supports similar prognostic power in females and males59.
Role of obesity and diabetes
Obesity and T2DM are not only risk factors for IHD and HFrEF,  but may also participate in 
the pathogenesis of HFpEF through low grade inflammation and microvascular disease15,90-92, 
Figure 4. The adipose tissue is highly metabolically active through the excretion of both pro- 
Figure 4. Overview of potential pathogenic mechanisms caused by obesity and insulin resistance 
contributing to the evolution of obesity related HF or HFpEF. 
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and anti-inflammatory mediators or adipokines, such as leptin or adiponectin. In addition, the 
adipose tissue is involved in the NP clearance via secretion of neprilysin and expression of 
the degradation receptor, NP receptor C93. Obesity also leads to increased aldosterone levels, 
both through RAAS activation, through adipokine induced adrenal stimulation, and through 
direct production of aldosterone from adipose tissue92,94. Moreover, obesity and insulin-
resistance lead to oxidative stress and an imbalance in the somatotropic axis, thereby further 
amplifying the cardio-metabolic risk-profile95. 
Despite being a risk factor for incident HF, obesity is associated with better prognosis in 
manifest HFrEF, referred to as the obesity paradox96,97. Whether the obesity paradox manifests 
a subgroup of patients with better reserve capacity or less severe disease, or if there is a 
mechanistic link between better prognosis and obesity is not clear98. 
Metabolic biomarkers
Insulin-like growth factor 1 
Insulin-like growth factor 1 (IGF-1) is a peptide hormone, structurally similar to insulin, 
produced in most cells. Circulating IGF-1 is mainly produced in the liver. IGF-1 is the effector 
peptide of GH acting through the IGF-1 receptor which resembles the insulin-receptor. In 
addition to metabolic and anabolic effects, IGF-1 stimulates myocardial contractility and has 
anti-inflammatory effects 99,100. IGF-1 levels are mainly reduced in HFrEF100, but normal101 or 
even increased concentrations have been reported in less severe HF102. These discrepancies 
are not fully understood, but are possibly explained by IGF-1 concentrations being dependent 
on age, severity of HF, and assay variability100. 
 In HFrEF, lower IGF-1 concentrations are associated with a catabolic state with cytokine 
activation, endothelial dysfunction, adverse remodeling, impaired skeletal muscle function, 
and worse outcomes103-105.  IGF-1 is believed to exert inotropic actions through increased 
intracellular Ca2+ transients and sensitivity, and through a shift in myosin isoforms. Thus, 
suppression of IGF-1 production or inhibition of IGF-1 could contribute to HF severity 
in HFrEF100,106. Moreover, administration of GH in HFrEF increases IGF-1 and improves 
myocardial function and cardiac output100.
Insulin-like growth factor binding protein 1
In general, decreased IGF-1 activity may be secondary to impaired GH-secretion, GH 
resistance, increased inhibition of IGF-1, malnutrition, or insulin-deficiency100. The activity 
of IGF-1 is tightly regulated by insulin-like growth factor binding proteins (IGFBPs) where 
IGFBP-1 is considered particularly important for IGF-1 activity regulation. Although present 
in much lower concentrations than IGFBP-3, IGFBP-1 is usually unsaturated and has a high 
diurnal variability and thereby accounts for the greatest changes in IGF-1 activity. IGFBP-1 
has numerous IGF-1 inhibitory actions such as peripheral binding of IGF-1, potent inhibition 
of IGF-1 at receptor level107, and inhibition of IGF-1 production in the liver, independently 
of insulin108,109.
The role of IGFBP-1 besides regulation of IGF-1 is still largely unexplored. IGFBP-1 may 
even potentiate the effects of IGF-1107 and it may also have IGF-1 independent actions110. 
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While obesity and peripheral insulin resistance are associated with lower IGFBP-1, high 
IGFBP-1 is associated with female sex, older age, lower body mass index (BMI), and lower 
levels of insulin111. Oxidative stress, hypoxia, inflammation, stress hormones, malnutrition, 
and insulin deficiency, all of which may be present in, and have a role in the evolution of 
both HFrEF and HFpEF, increase IGFBP-1112-114. Increased levels of IGFBP-1 have been 
described in hypertrophic cardiomyopathy and during congestion IGF-1 decreased and 
IGFBP-1 increased115. Although higher levels of IGFBP-1 are associated with a favorable 
lipid-profile, absence of insulin resistance, and female sex; high levels of IGFBP-1 have 
been associated with risk for incident HF111. Furthermore, high levels of IGFBP-1 have been 
associated with hospitalization for HF after myocardial infarction116.
Adipokines- leptin and adiponectin
Leptin and adiponectin are cytokines, commonly referred to as adipokines, secreted mainly 
by the adipose tissue. In obesity, there is hyperleptinemia and levels of adiponectin are 
reduced. Leptin regulates satiety and is considered proinflammatory. In contrast, adiponectin 
is regarded as cardioprotective in reducing oxidative stress and inflammation, both in the heart 
and the vasculature. Hence, higher adiponectin levels in healthy individuals are associated 
with a favourable cardiovascular risk profile117,118.
The role of leptin and adiponectin in HF is complex. As obesity, leptin and adiponectin can 
behave paradoxically in HF. Despite a catabolic state, leptin may be elevated119 and higher 
concentrations of leptin are associated with better prognosis in HFrEF120. Correspondingly, 
higher levels of adiponectin are, despite the presumed beneficial effects of adiponectin, 
associated with worse outcomes in HF. This is sometimes referred to as the adiponectin 
paradox121. 
Leptin
Although mainly produced by adipocytes, leptin is also found in various cell types such 
as cardiomyocytes and smooth muscle cells. High levels of leptin are associated with 
obesity, hypertension and insulin resistance117. Besides metabolic effects, leptin has various 
cardiovascular effects. Leptin mediates positive inotropic and chronotropic effects through 
central SNS stimulation and RAAS activation122. Leptin is also believed modulate vascular 
function via stimulation of endothelial NO-synthesis. However, in hyperleptinemia, there 
is a reduced response to leptin through interaction with inflammatory biomarkers, resulting 
in inhibition of the NO generating effect of leptin123. This suggests a link between leptin 
resistance, inflammation and endothelial dysfunction122,123. 
Elevated plasma leptin has been reported in established HFrEF119,124. High concentrations of 
leptin have also been associated with arterial stiffness125. Additionally, an association between 
leptin and diastolic dysfunction in the general population and in patients with CAD has been 
described126,127. Interestingly, this association was more prominent in women. Hence, leptin 
is believed to play a role in the pathogenesis of HFpEF128,129.
Adiponectin
Adiponectin, existing as polymers, is abundantly present in plasma and the highest levels are 
found in lean subjects. Similarly to leptin, women have higher adiponectin levels than men118. 
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Low levels of adiponectin are associated with comorbidities related to HF like obesity, insulin 
resistance, and hypertension.  Adiponectin is considered a marker of, or potentially even a 
factor effectuating, cardio-protection130. Adiponectin deficiency leads to hypertension, LV 
hypertrophy, diastolic dysfunction, and, in the presence of pressure overload, cardiovascular 
alterations resembling HFpEF in experimental models131. Correspondingly, overexpression 
of adiponectin attenuates cardiac remodeling130. 
In HFpEF adiponectin is still poorly studied, although experimental data support adiponectin 
deficiency in the pathogenesis of HFpEF130,131. An association between diastolic dysfunction 
and lower adiponectin concentrations was found in a small study of patients with EF >50% 
and mild HFpEF132, similar to findings in patients with CAD133,134.
Despite low adiponectin levels being associated with the evolution of HF, adiponectin levels 
are increased and associated with poor prognosis in manifest HFrEF135-137. The reason for 
the adiponectin paradox in HFrEF is not well known but adiponectin concentrations are 
positively associated with severity of HF and NP concentrations in congestive HF135,137. 
Furthermore NPs increase the production of adiponectin in adipocytes from HF patients 138 
and adiponectin resistance has been described in HFrEF139. 
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AIMS
The overall aim was to investigate metabolic biomarkers and the impact of sex regarding 
PRO and NPs across the ejection fraction spectrum in patients with HF with particular focus 
on HFpEF. 
Specific aims were:
To investigate whether the impairment of the IGF-1 axis shown in HFrEF exists also in 
HFpEF through assessment of IGF-1 and IGFBP-1 (Study I).
To investigate leptin and adiponectin concentrations and their prognostic associations in 
HFpEF and HFrEF, and whether the obesity paradox is present in HFpEF (Study II). 
To assess potential sex differences in PROs in HFpEF, including the associations with HF 
severity and outcomes (Study III).
To assess the impact of sex on NT-proBNP concentrations and prognosis in HF across the 
ejection fraction spectrum (Study IV). 
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Study I II III IV
Aim To assess if HFpEF 
and HFrEF share 
features of anabolic 
impairment regarding 
IGF-1  and IGFBP-1
To assess levels 
of leptin and 
adiponectin and 
whether the obesity 
paradox exists in 
HFpEF
To investigate 
potential 
sex-specific 
differences in  
PROs in HFpEF
To assess the impact of 
sex on concentrations 
of NT-proBNP, and 
associations with 
clinical characteristics 
and outcomes of high
NT-proBNP across the 
HF phenotypes
Design Prospective observational cohort studies Registry based cohort 
study
Time 
of data 
collection
HFpEF: 2007-2011
HFrEF: 2009-2014 2007-2011 2000-2012
Data 
source KaRen, MetAnEnd, Hälsa Ohälsa KaRen SwedeHF
Study 
population
Chronic HFpEF, HFrEF and controls from 
the normal population
Chronic HFpEF Chronic HF across the 
EF spectrum
Patients 300
85 HFpEF
79 HFrEF
136 Controls
234
84 HFpEF
79 HFrEF
71 Controls
378 HFpEF 15,849
1811 HFpEF
2122 HFmrEF
5914 HFrEF
Outcomes HFpEF: HF hospitalization or death
HFrEF: Transplantation, LV assist device, 
or death
HF 
hospitalization 
or death
1. HF hospitalization 
or death
2. All-cause death
Main 
statistical 
analyses
ANCOVA, Pearson’s correlation, Kaplan 
Meyer, Cox regression
Spearman’s 
correlation, Cox 
Regression
Logistic regression, 
Kaplan Meyer, Cox 
Regression
Results/
Conclusion
Both HF phenotypes 
share impairment 
in the IGF-1 axis 
through increased 
IGFBP-1. IGF-1 was 
lower and associated 
with outcomes in 
HFrEF only.
HFpEF and 
HFrEF share 
elevated leptin 
and adiponectin, 
but the obesity 
paradox regarding 
leptin could only 
be confirmed in 
HFrEF.
Females express  
worse general 
QoL. Poor 
QoL seems less 
explained by HF 
in females and 
was associated 
with worse 
outcome in 
males only.
Despite higher 
concentrations in 
females, determinants 
of concentrations 
and association with 
prognosis were similar 
in females and males.
THESIS AT A GLANCE
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Data sources
Study I-III the Karolinska Rennes 
The Karolinska Rennes study (KaRen) was an observational, prospective, multicentre study 
conducted in France and Sweden during 2007-2011. The primary aim was to investigate the 
prevalence and prognostic role of electrical dys-synchrony in HFpEF. Predefined sub-studies 
were echocardiography, cardiopulmonary exercise testing, serological biomarkers, and PRO. 
Patients were included at hospitalization for acute decompensated HFpEF and inclusion 
criteria were: (1) Acute presentation with clinical signs and symptoms of HF according to the 
Framingham criteria; (2) LVEF ≥45 % by echocardiography during the first 72 h; and (3) BNP 
>100pg/mL or NT-proBNP >300pg/mL. The aim was to study a real-life cohort of HFpEF 
and the exclusion criteria were mainly factors which prevented the patients from completing 
the study. Key exclusion criteria were: evidence of primary hypertrophic or restrictive 
cardiomyopathy or infiltrative heart disease, isolated right HF, pericardial constriction, chronic 
pulmonary disease requiring oxygen, end-stage renal disease requiring dialysis, and anticipated 
or indication for cardiac surgery or percutaneous intervention. Patients were scheduled for a 
follow up visit in stable state 4-8 weeks after the acute presentation and were then followed for 
at least 18 months. In total 539 patients were included and 438 patients attended the follow up 
visit. The primary outcome was hospitalization for HF or all-cause death140. 
In Study I and II only patients from the pre-specified KaRen biomarker study were 
investigated and for Study III all patients with complete PRO assessment at the follow up 
visit were included. 
Study I-II MetAnEnd
Patients with HFrEF, were obtained from the Metabolic Anabolic Endothelial Function Heart 
Failure study cohort (MetAnEnd-HF) at Karolinska University Hospital. Between January 
2009 and September 2014, patients with advanced HF and EF <40% referred to the hospital 
were included in MetAnEnd-HF. Exclusion criteria were only inability to participate or 
participation in a pharmacological intervention study. The patients were followed prospectively 
and the composite endpoint was all-cause death, implantation of LV assist device, or heart 
transplantation. Information regarding vital status, implantation of LV assist device or heart 
transplantation was obtained from patient charts and the Population Register in December 2014. 
Study I-II Hälsa Ohälsa
The control population for the biomarker studies was obtained from the Hälsa Ohälsa study 
conducted in 1995- 1998. In the study, individuals aged 18 and above from the general 
population were randomly selected through their personal identification number for a 
questionnaire study concerning health. Of these, 488 again randomly selected, individuals 
across age-groups were invited to a medical examination including biomarker analysis. 
Individuals free from self-reported cardiovascular disease or known hypertension were 
included as controls in Study I and II118,141. 
Study IV- the Swedish Heart Failure Registry 
The Swedish Heart Failure Registry (SwedeHF, www.swedehf.se) is a national quality 
registry founded in 2000. It covers almost 90% of the hospitals and about 10% of primary care 
METHODS
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centres in Sweden. The inclusion criterion is “Clinician–judged HF”. About 80 variables 
are recorded at discharge from hospital or after outpatient clinic visit in a web-based case 
report form, managed by Uppsala Clinical Research Center, Uppsala, Sweden (www.ucr.
uu.se). In about 90% of the registrations, EF is reported categorized as <30, 30-39, 40-49, 
and ≥50 %, enabling differentiation between the three different HF phenotypes142. To obtain 
outcome data the registry is linked to The Population and the Patient Registries administered 
by The Swedish Board of Health and Welfare (www.socialstyrelsen.se), through the Swedish 
personal identification number.
Instruments for patient reported outcome 
The EQ-5D-3L is a generic QoL instrument. Part one is descriptive with five dimensions; 
mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. There are three 
response options for each dimension (no problems, some problems, and extreme problems). 
Part two is the EuroQoL Visual Analogue Scale (EQ-VAS), which records the patient’s self-
rated global health on a VAS-scale. The endpoints are labelled “Worst imaginable health 
state” (0) and “Best Imaginable Health State” (100). Hence higher values of EQ-VAS denotes 
better QoL143-145.
The MLHFQ is a HF specific instrument. Totally 21 items cover the effects on QoL of 
functional limitations, symptoms, and psychological reactions associated with HF or HF 
treatment. The response options range from no limitation (0) to very much limited (5). A total 
score of 0-105 is given and a higher score will indicate worse QoL146,147.
Statistics
Data are displayed as counts (%) and median and interquartile range (IQR), except for Study 
III where mean and standard deviation (SD) were used for normally distributed, continuous 
baseline characteristics. Continuous variables were analysed with non-parametric Mann-
Whitney U test or Kruskal-Wallis, or t-test as appropriate. Proportions were compared with 
Fisher’s exact test or Chi2-test depending on frequency distribution. 
Biomarker data in Study I and II and QoL data in Study III were analysed by the analysis 
of covariance (ANCOVA) with adjustment for clinically relevant variables. Associations 
were assessed by Pearson’s (Study I-II) and Spearman’s correlations (Study III), and with 
multivariable logistic regression (Study IV).  Unadjusted survivor functions were estimated 
through the Kaplan-Meier method (Study IV), and associations with outcomes were analysed 
with Cox Proportional Hazards models (Study I-IV). Results from regression models are 
presented as odds ratio (OR) or hazard ratio (HR) as appropriate and 95% confidence interval 
(CI). To test significant differences between sexes in Study IV, interaction terms between 
sex and the other variables considered was included in the multivariable models regression 
models. The presence of missing data in Study IV was addressed through multiple imputation 
with chained equations (n=10), run in blocks defined according to HF type and sex. The 
statistical significance level was set to 0.05 in all analyses except for correlations in Study 
I and II where the α-level was set to 0.003 and 0.002 respectively due to multiple analyses 
(Bonferroni adjustment). All- p-values were 2-sided. 
Statistical analyses were performed in IBM SPSS Statistics, version 22 (IBM Corp., Armonk, 
NY) (Study I and II) and Stata 14.1 (StataCorp, College Station, Texas) (Study III-IV).
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Ethical considerations
All the studies were performed in accordance with good clinical practice guidelines and the 
Declaration of Helsinki and all patients provided written informed consent148. For registration 
in SwedeHF, individual consent is not required but the patients are informed and able to opt 
out. The establishment of SwedeHF and all studies in this thesis were approved by ethical 
committees in Sweden.
Description of studies
Study I 
Aim 
To investigate concentrations of IGF-1 and IGFBP-1, associations of these with HF severity 
and outcomes, and whether impairment of the IGF-1 axis in HFrEF exists also in HFpEF.
Patients 
Patients with HFpEF from the KaRen study (n=85), with HFrEF from MetAnEnd-HF (n=79), 
and individuals without self-reported cardiovascular disease aged 40 years and above from 
the Hälsa Ohälsa study (n=136) were included in the analysis. 
Methods
The patients were examined and underwent echocardiography in stable state. Fasting 
blood samples were collected in and IGF-1 and IGFBP-1 analyses performed by in-house 
radioimmuno-assays. Of note, due to the age-dependency of IGF-1 (decreasing concentrations 
with increasing age), age adjusted IGF-1 SD-score was calculated based on the regression of 
IGF-1 concentrations in healthy149. Concentrations of IGF-1 and IGFBP-1, as well as their 
associations with other relevant biomarkers and outcomes were assessed.
Endpoints
For HFpEF time to HF hospitalization or all-cause death, for HFrEF time to implantation of 
LV assist device, heart transplantation, or all-cause death.
 
Study II
Aim
To investigate concentrations of leptin and adiponectin, associations with HF severity and 
outcomes and whether the reverse metabolic profile is present in HFpEF as in HFrEF.
Patients
Patients with HFpEF from the KaRen study (n=84), patients with HFrEF from MetAnEnd-
HF (n=79), and individuals aged 60 years or above without self-reported cardiovascular from 
the Hälsa Ohälsa study (n=71) were included in the analysis. 
Methods 
The patients were examined and underwent echocardiography in stable state. Fasting blood 
samples were collected and leptin and adiponectin analyses were performed by radio-
immunoassays Merck Millipore® (HL-81 K and HADP-61K). Concentrations of leptin and 
adiponectin and their associations with other relevant biomarkers and outcomes were assessed.
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Endpoints
For HFpEF time to HF hospitalization or all-cause death, for HFrEF time to implantation of 
LV assist device, heart transplantation, or all-cause death.
Study III
Aim
To assess PRO in HFpEF and potential sex differences.
Patients
Of the 539 patients included in KaRen, 438 patients attended the follow up visit. Of these 
387 patients had complete assessments of PRO. Since the KaRen study was designed prior 
to the new definition of HFpEF, 9 patients with EF <50% were excluded, and the remaining 
378 patients were analysed. 
Methods 
The patients underwent clinical examination, ECG, and echocardiography at the 4-8 weeks 
visit in stable state. Two validated PRO instruments were used, the generic EQ-5D-3L and 
the HF-specific MLHFQ. Self-reported QoL was assessed and the associations of QoL with 
HF severity and outcomes. 
Endpoint
Time to first HF hospitalization or all-cause death. 
Study IV
Aim
To assess the impact of sex on NT-proBNP concentrations, associations between clinical 
characteristics and high NT-proBNP, and the associations with outcomes in HFpEF, HFmrEF, 
and HFrEF.
 
Patients 
Between May 11th 2000 and December 31st 2012, 36,255 outpatient registrations were 
recorded in SwedeHF. Excluding patients with missing EF, follow up <1 day, missing NT-
proBNP, and repeated registrations left 9847 patients for analysis. In the case of more than 
one registration, the first assessment was considered. 
Methods
Concentrations of NT-proBNP were assessed in females and males in all EF phenotypes 
respectively. Associations between NT-proBNP above the median in females and males in 
each HF-type, and clinical characteristics and outcomes were investigated. The majority of 
health facilities in Sweden use the NT-proBNP analysis by Roche Diagnostics, Bromma, 
Sweden (www.equalis.se).
Endpoints
The primary endpoint was time to HF hospitalization or all-cause death and the secondary 
endpoint time to all-cause death. End of follow-up was December 31st 2012.
         Heart failure: Biomarkers, ejection fraction, and sex
27
Study I
Baseline characteristics
Compared with HFrEF, patients with HFpEF were older, more commonly female, with 
lower NYHA class, better renal function, higher BMI, and lower NT-proBNP. There were 
no statistically significant differences in comorbidities although numerically IHD, defined as 
previous coronary artery by-pass grafting and percutaneous coronary intervention, was more 
common in HFrEF. Use of neurohormonal antagonists and diuretics were more common in 
HFrEF, whereas calcium channel blockers were more common in HFpEF. Selected baseline 
characteristics are shown in Table 1. The controls were younger and had lower BMI compared 
with the HF patients. Blood pressure and sex ratio in controls were similar to in HFpEF. 
Concentrations of IGF-1
Median (IQR) concentrations of IGF-1 were: 173 (137-207) in HFpEF vs. 149 (105-219) in 
HFrEF vs. 163 (133-205) μg/L in controls (p overall= 0.002). Age adjusted IGF-1 SD-scores 
were 1.21 (0.57-1.96) vs. 0.09 (-1.40–1.62) vs. 0.22 (-0.47-0.96) arbitrary units, respectively 
(p overall <0.001). Concentrations and pair-wise comparisons are shown in Figure 5, and in 
men only in Figure 6. The difference between IGF-1 concentrations in HFpEF and HFrEF 
was significant also after adjustment for sex, BMI, insulin, and NYHA class (p=0.032).  
RESULTS
Table 1. Baseline characteristics of the patients in Study I expressed as median and lower and upper 
quartiles and numbers and percentage.
HFpEF 
n=85
HFrEF 
n=79
Control 
n=136
p-value
HFpEF:
HFrEF
HFpEF:
control
HFrEF:
control
Age years 73 (67;79) 64 (52;69) 58 (49;66) <0.001 <0.001 0.018
Female 44 (52) 13 (16) 68 (50) <0.001 0.890 <0.001
NYHA I
II
III
IV
19(22)
46(54)
20 (24)
0
1 (1)
4 (5)
65 (82)
9(11)
<0.001
BMI kg/m2 28 (25;33) 27 (23;30) 25 (23;27) 0.036 <0.001 0.017
Systolic blood 
pressure mmHg 140 (128;153) 108 (96;122) 137 (126;149) <0.001 0.100 <0.001
Pulse pressure mmHg 65 (50;75) 39 (30;50) 50 (43;60) <0.001 <0.001 <0.001
EF % 64 (55;68) 22 (15;28) <0.001
NT-proBNP pg/mL 983 (463;2303)
3425 
(1333;5988) <0.001
HOMA-IR 3.5 (2.0;5.9) 2.6 (1.4;5.3) 2.0 (1.3;2.8) 0.250 <0.001 0.004
eGFR mL/min/1.73m2 66 (51;80) 54 (39;66) 76 (68;85) <0.001 <0.001 0.001
Hemoglobin g/L 13.1 (12.2;14.1)
13.3 
(12.2;14.4)
14.3 
(13.5;15.2) 0.497 <0.001 <0.001
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In patients with functional class NYHA II-III age adjusted IGF-1 SD-scores were 1,31 (0.70-
2.28) in HFpEF (n=66) vs. 0. 24 (-1.32-1.65) in HFrEF (n=69) (p<0.001 crude and p=0.012 
adjusted for sex, BMI, and insulin).
Concentrations of IGFBP-1
In HFpEF and HFrEF, IGFBP-1 was increased compared to controls. Median (IQR) IGFBP-1 
was 48 (28-79) μg/L in HFpEF vs. 65 (29-101) in HFrEF vs. 27 (14-35) in controls (p overall 
<0.001). When adjusted for age, sex, BMI, and insulin; IGFBP-1 remained significantly higher 
in HFrEF and HFpEF compared to controls (p <0.001 for both), but lower in HFpEF compared 
to HFrEF (p=0.021). When adding NYHA class to the model as a marker of HF severity, the 
difference between HFpEF and HFrEF was no longer significant (p=0.451). Coherently, in 
patients with NYHA class II-III, levels of IGFBP-1 were similar in HFpEF 48 (28-78) and 
HFrEF 60 (29-91) (unadjusted p=0.369 and adjusted for sex, age, BMI, and insulin, p=0.262), 
Figure 5.  
 
The analyses of IGF-1 and IGFBP-1 were repeated in men only. The findings were largely 
similar, except that no measure of IGF-1 significantly differed between patients with HFpEF 
and controls, Figure 6.
Figure 5. Concentrations of IGF-1 (A), IGFBP-1 (C), and age-adjusted IGF-1 SD score (B) in 
HFpEF, HFrEF, and controls. P denotes crude comparisons between groups. 
Figure 6. Concentrations of IGF-1 (A), IGFBP-1 (C), and age-adjusted IGF-1 SD score (B) in men 
with HFpEF, HFrEF, and male controls. P denotes crude comparisons between groups. 
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Associations with HF-severity
There was a negative association between IGF-1 and IGFBP-1 in HFpEF (r=-0.390, 
p<0.001); and approaching significance in HFrEF (r= -0.320, p=0.004, α-level 0.003). There 
was no significant association between IGF-1 and age, NT-proBNP, or estimated glomerular 
filtration rate (eGFR) in neither HFpEF nor HFrEF.  In contrast, NT-proBNP and IGFBP-1 
were associated in both HFpEF (r= 0.458, p<0.001) and HFrEF (r=0.533, p<0.001). In both 
HFpEF and HFrEF; IGFBP-1 was associated with insulin (r= -0.430, p<0.001; and  r=-0.383, 
p=0.001). Results in men only were similar. Selected correlations are shown in Figure 7. 
Associations with outcomes
Median (IQR) follow-up time was 576 (468-1349) days in HFpEF and 403 (195-992) days in 
HFrEF. The endpoint occurred in 35 (41%) patients with HFpEF of which 6 patients (17%) 
died and 29 (83%) were hospitalized for HF. Corresponding data for HFrEF was 50 (63%) 
events, of which 27 (54%) were deaths and 23 (46%) implantation of LV assist device or 
heart transplantation.
Hazard ratios per ln unit increase in IGF-1, IGF-1 SD-score and IGFBP-1 for the composite 
endpoints in HFpEF and HFrEF respectively are shown in Figure 8. In HFpEF, there 
was no association between baseline IGF-1 or IGF-1 SD-score and outcomes, in uni- or 
multivariable analyses. In HFrEF, higher IGF-1, and likewise higher age-adjusted as SD-
score, was associated with better outcome.
Regarding IGFBP-1 there were no associations with outcomes in neither HFpEF nor HFrEF. 
Results in men were similar. 
Figure 7. Pearson’s correlations between IGF-1, IGBP-1, and NT-proBNP in HFpEF and HFrEF. 
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Study II
Baseline characteristics
Compared to HFrEF, patients with HFpEF were, as in Study I, older (median 73 vs. 64 years, 
p<0.001), more commonly female (52 vs 16%, p<0.001), and in lower NYHA class. Patients 
with HFpEF also had better renal function, higher BMI, and lower NT-proBNP (median 966 
vs. 3425 pg/mL, p<0.001). Regarding comorbidities there were no statistically significant 
differences but previous coronary artery by-pass grafting and percutaneous coronary 
intervention were numerically more common in HFrEF, as in Study I. Therapy also differed 
between HFpEF and HFrEF similar to in Study I. 
The controls were in between HFpEF and HFrEF regarding age (median 67 years). BMI 
was lower in controls compared to in HFpEF, whereas similar to in HFrEF. Considering 
the controls did not have known hypertension, surprisingly they had higher blood pressure 
compared to both HF phenotypes. Median systolic blood pressure was 140 mmHg in HFpEF 
vs. 108 in HFrEF vs. 165 in controls (p for all comparisons <0.001). 
Concentrations of leptin 
Leptin concentrations were median (IQR) 23.1 (10.2-51.0) in HFpEF vs. 15.0 (6.2-33.2) in 
HFrEF vs. 10.8 (5.4-18.9) ng/mL in controls (p overall <0.001). Concentrations of leptin were 
Figure 8. Association between IGF-1 (crude and age adjusted SD-score), IGFBP-1, and NT-proBNP 
with the composites of HF hospitalization or death in HFpEF and implantation of LV assist device, 
heart transplantation, or death in HFrEF. Insulin resistance (HOMA-IR) and HF severity, measured 
as NT-proBNP, were adjusted for in the multivariable models. 
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higher in HFpEF than in HFrEF (p=0.007), however there was no difference between the HF 
groups when adjusted for sex, BMI, and age (p=0.123), nor when NYHA class was added to 
the model as adjustment for HF severity (p=0.834). Results in men only were similar. 
Concentrations of adiponectin
Crude levels of adiponectin did not differ between groups, 11.8 (7.9-20.1) μg/L in HFpEF 
vs. 13.7 (7.0-21.1) in HFrEF vs. 10.5 (7.4-15.1) in controls (p overall 0.159). There was no 
significant difference between the HF groups crude or adjusted for age, sex, BMI, and NYHA 
class. In analyses of men only, adiponectin, adjusted for BMI and age, was higher in both 
HFpEF (p=0.044) and HFrEF (p=0.001) compared to in controls. Absolute concentrations 
and adjusted pair-wise comparisons for the entire cohort and men separately, are shown in 
Figure 9. 
Associations with biomarkers
 In all groups, leptin was positively associated with BMI (HFpEF r=0.740, HFrEF r=0.595, 
and controls r=0.593,  p for all <0.001). Similarly, there was a positive association between 
leptin and insulin (HFpEF r=0.685, HFrEF r=0.487, and controls r=0.358 p <0.001 for all). In 
HFrEF only, there was a significant association of leptin with NT-proBNP(r=-0.364 p=0.001).
  
Adiponectin showed an inverse association with BMI in the heart failure groups (r=-0.386 
p<0.001 in HFpEF and r=-0.379 p=0.001 in HFrEF), but not in controls (r=-0.154 p=0.202). 
In HFrEF, adiponectin was associated with with NT-proBNP (r=0.396 p<0.001), however 
not in HFpEF considering the adjusted α-level of 0.002 (r=0.238, p=0.030), Figure 10 a-d.
Figure 9. Crude levels of leptin and adiponectin in the entire (a+c)  cohort and  men only (b+d). P for 
pairwise comparisons and overall, adjusted for age, sex, and BMI (a+c), and for age and BMI (b+d).
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Associations with outcomes
Median follow-up time (IQR) was 572 (467-1369) days in HFpEF and 402 (196-873) days in 
HFrEF. The endpoint occurred in 34 (40%) patients with HFpEF of which 6 patients (18%) 
died and 28 (82%) were hospitalized for HF. Corresponding data in HFrEF were 50 (63%) 
events, of which 27 (54%) were deaths and 23 (46%) received LV assist device or were 
transplanted. Figure 11 shows HRs per unit ln increase in leptin and adiponectin in HFpEF 
and HFrEF for the composite endpoints.
Figure 10. Associations between the adipokines and NT-proBNP in HFpEF and HFrEF.
Figure 11. Association between leptin, adiponectin, NT-proBNP, and BMI and the composites of 
HF hospitalization or death in HFpEF and implantation of LV assist device, heart transplantation, or 
death in HFrEF. 
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High leptin levels were associated with reduced the risk of the composite endpoint in HFrEF 
only, both crude and adjusted for age and sex. When adjusting for HF severity by including 
NT-proBNP in the model, the association was no longer significant.  
While there was no association between adiponectin and the composite outcome in HFpEF, 
hihger adiponectin was associated increased risk in HFrEF after adjustment for age and sex, 
HR 2.88 (95% CI 1.02-8.14, p=0.045). The association was however not independent of HF 
severity. 
Study III
Baseline characteristics
A total of 378 patients were included in the analyses, Figure 12. Of these, 215 were women 
(57%). Women were older and had higher EF. There were also signs of higher filling pressures, 
measured as E/e’ in women. Levels of NT-proBNP were similar, median (IQR), 1408 (507- 
2369) vs. 1480 (611- 2840) ng/L (p=0.17). In contrast, in the cohort of patients where BNP was 
assessed (n=35), BNP levels were higher in women than in men, median (IQR), 301 (229- 476) 
vs. 108 (98- 570) ng/L (p=0.041). Kidney function, was similar in both sexes.
Comorbidities were no different across sexes except for women having a lower prevalence 
of CAD (27 vs. 38%, p=0.016), and anaemia (35 vs. 51%, p=0.004). Therapy did not differ 
between sexes. Baseline characteristics are shown in Table 2.
Figure 12. Study outline, patient selection and follow up. 
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Table 2. Baseline characteristics by sex, Study 3.  To include both BNP and NT-proBNP in the 
multivariable analyses, quartiles were calculated based on the entire population. For NT-proBNP: 
Q1 <532, Q2 532-1438, Q3 1439-2641, and Q4 >2641ng/L; and for BNP: Q1 <125, Q2 125-277, 
Q3 278-570, and >570 ng/L. 
Female Male p-value
Clinical data, mean (SD) n 215 163
Age (years) 77 (9) 75 (9) 0.014
EF (%) 64 (7) 62 (6) 0.005
E/e’ 14 (7) 11 (5) <0.001
SBP (mmHg) 137 (24) 139 (24) 0.45
BMI (kg/m2) 29 (7) 29 (5) 0.93
NYHA class, n (%) I 17 (9) 27 (17)
0.009
II 132 (68) 90 (57)
III 45 (23) 34 (22)
IV 1 (0.5) 6 (4)
Biochemistry, median(IQR)
Haemoglobin (g/L) 125 (110, 132) 129 (110, 139) 0.13
eGFR CKDEPI (mL/min) 74 (66, 80) 72 (65, 83) 0.97
NT-proBNP (ng/L) n=312 1408 (507, 2369) 1480 (611, 2840) 0.17
BNP (ng/L) n=35 301 (229, 476) 108 (98, 570) 0.041
Comorbidities, n (%)
CAD 58 (27) 62 (38) 0.022
Atrial fibrillation or flutter 132 (61) 107 (67) 0.34
Hypertension 173 (81) 128 (79) 0.64
COPD 29 (14) 24 (15) 0.73
T2DM 55 (26) 45 (28) 0.66
Anaemia 68 (35) 78 (51) 0.004
Treatment, n (%)
ACEi or ARB 155 (71) 114 (70) 0.98
Potassium sparing diuretic 49 (23) 42 (26) 0.48
Loop diuretic 170 (80) 132 (82) 0.56
Calcium channel blocker 57 (27) 43 (27) 0.99
β-blocker 149 (69) 115 (71) 0.72
SBP, systolic blood pressure; COPD, chronic obstructive pulmonary disease; ACEi, angiotensin 
converting enzyme inhibitor; ARB, angiotensin receptor blocker. 
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Quality of life
Women expressed more difficulties than men related to mobility (53 vs. 41%, p=0.019), 
usual activities (46 vs. 33%, p=0.013), and anxiety and depression (51 vs. 39%, p=0.013) 
in EQ-5D-3L. Self-care (22 vs. 17%, p=0.230), and pain/discomfort (60 vs. 53%, p=0.179) 
were not significantly different. In EQ-VAS, women rated worse global QoL than men [mean 
(SD), 57 (20) vs. 61 (19), p=0.027]. After adjustment for age and NPs the difference was 
still significant (p=0.010). When, instead, adjusting for age and NYHA class, there was only 
a trend towards statistical significance (p=0.056). MLHFQ was similar in women and men, 
[mean (SD), 31(21) vs. 29 (21), p=0.329], Figure 13. 
Figure 13. Percentage of patients rating problems in EQ-5D-3L part 1, and rated QoL in EQ-VAS and 
MLHFQ in women and men.  
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Associations between quality of life and markers of HF severity 
Both instruments were associated with HF severity measured as NYHA class and as levels of 
NPs. Spearman’s correlations between MLHFQ and NYHA class were in women; rs 0.37 vs. 
in men 0.41, p for both <0.001. Corresponding data for the associations between MLHFQ and 
quartiles of NPs were in women; rs 0.21, p=0.003 vs. in men 0.27, p<0.001. The associations 
of EQ-VAS with NYHA class were in women rs -0.28, p<0.001 and in men rs -0.45, p<0.001, 
and for EQ-VAS and NPs, rs -0.17, p=0.018 in women and rs= -0.27, p<0.001 in men. 
Associations between QoL and Outcomes
Associations between MLHFQ/EQ-VAS and outcomes in women and men are reported in 
Figure 14. In women, neither MLHFQ nor EQ-VAS were associated with the composite of 
HF hospitalization or death. In men, 5 units increase in MLHFQ (worse QoL) was associated 
with a 6% increase in risk of the composite outcome [HR 1.06, 95% CI 1.01-1.11, p 0.026]. 
Coherently, 5 units increase in EQ-VAS (better QoL) was associated with a 7% reduction in 
risk (HR 0.93, 95% CI 0.88-0.98, p=0.010).  The association between EQ-VAS and risk of 
adverse outcome persisted after adjustment for age, kidney function (eGFR) and comorbidities 
(T2DM, anaemia, chronic obstructive pulmonary disease, and IHD) (HR 0.93, 95% CI 0.088-
0.99, p=0.020). The association between MLHFQ and the composite outcome approximated 
statistical significance (HR 1.05, 95% CI 1.00-1.11, 0.059). The associations were however not 
independent of HF severity and were lost when NPs were added to the model.
 
Figure 14. Associations between MLHFQ and EQ-VAS and the composite of HF hospitalization and 
death. Model 2 includes adjustment for age, kidney function and relevant comorbidities (T2DM, anaemia, 
chronic obstructive pulmonary disease, and IHD), and in Model 3 with addition of quartiles of NPs.
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Figure 15. Study population
Study IV
Baseline characteristics
Of 9847 patients, 1811 (18%) had HFpEF, 2122 (22%) HFmrEF, and 5914 (60%) HFrEF, 
Figure 15. The proportion of females was higher in HFpEF (49%) vs. HFmrEF (35%) vs. 
HFrEF (25%). Females of all HF-phenotypes were older, had higher NYHA class, and better 
renal function as compared with males. The prevalence of T2DM, IHD, and anaemia was 
lower in females. Atrial fibrillation was less prevalent in females compared with males in 
HFpEF and HFrEF, whereas in HFmrEF, females were less likely to have hypertension and 
cancer. Except for more use of diuretics in females with HFpEF and HFmrEF and more use 
of statins in males regardless of EF, therapy was similar in both sexes. 
Concentrations of NT-proBNP
Concentrations of NT-proBNP were higher in females vs. males in all three HF types. Sex-
differences in NT-proBNP levels were consistent when rhythm status was considered (atrial 
fibrillation vs. no atrial fibrillation), except for in patients with HFmrEF where there was no 
statistically significant difference in females vs. males, Figure 16 A-C. 
Associations between clinical characteristics and high NT-proBNP
Independent associations between relevant demographics/clinical characteristics/ therapies 
and NT-proBNP are shown in Figure 17 A-C. Factors associated with high NT-proBNP 
concentrations were similar in both sexes across HF phenotypes with few exceptions. In 
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Figure 16 A-C. Concentrations of NT-proBNP in females and males, overall and by rhythm status. 
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HFpEF, hypertension was associated with high NT-proBNP in males but not in females 
(p-interaction sex*hypertension=0.015). In addition, there was a difference in association 
between mean arterial pressure >90 mmHg and high NT-proBNP in males vs. females 
(p-interaction 0.040). Diuretic use was also associated with increased odds of high NT-
proBNP in males but not in females (p-interaction=0.032). In HFmrEF, in females, whereas 
not in males, IHD was associated with high NT-proBNP (p-interaction 0.005). In HFrEF 
there was no significant interaction between the variables explored and sex. 
Prognostic associations of NT-ProBNP in females vs. males 
In HFpEF, over a median (IQR) follow-up of 2.1 (1.0-3.6) years, 100 deaths per 1000 
patient-years occurred in females vs. 107 in males. In HFmrEF rates were 89 vs. 100 per 
1000 patient-years over a follow-up of 2.0 (1.0-3.6) years, whereas in HFrEF they were 85 
vs. 89 per 1000 patient-years over a follow-up of 2.0 (0.9-3.6) years in females vs. males, 
respectively.  
Rates for the composite endpoint of HF hospitalization or all-cause death were 169 vs. 172 
per 1000 person-years in females vs. males in HFpEF, 188 vs. 171 in HFmrEF and 209 vs. 
243 in HFrEF. 
Figure 17 A-C. Associations between patient characteristics and high NT-proBNP in the three HF 
phenotypes. 
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Figure 18 show survival free of HF hospitalization together with crude and adjusted HRs 
for risk of the composite outcome associated with high NT-proBNP in HFpEF, HFmrEF, and 
HFrEF. NT-proBNP above median was associated with increased unadjusted and adjusted 
risk regardless of sex and EF. There were no significant interactions between sex and NT-
proBNP.
Figure 18. Survival free of HF hospitalization in the three HF phenotypes by sex and high vs. low 
NT-proBNP and hazard ratios for the composite endpoint in females and males. 
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GENERAL DISCUSSION
The principal findings of the four studies in this thesis are:
1. The impairments of the IGF-1 axis are more pronounced in HFrEF compared to in 
HFpEF and are associated with poor prognosis in HFrEF. Still, both EF phenotypes 
share increased levels of IGFBP-1, indicating inhibition of the IGF-1-axis. IGFBP-1 
was also associated with HF severity measured by NT-proBNP. Together with previous 
data, this suggests a potential mechanistic link between IGFBP-1 and NPs. 
2. HFpEF and HFrEF share elevated levels of leptin and adiponectin. The obesity para-
dox, where higher levels of leptin are associated with better prognosis, was only dem-
onstrated in HFrEF, pointing towards a more conventional metabolic profile in HFpEF. 
3. Women with HFpEF express worse global QoL than men. Overall, QoL was only 
weakly associated with measures of HF severity and the associations were weaker in 
women. In men only, poor QoL was associated with worse outcome. Overall, the results 
suggest that to improve QoL in HFpEF patients, in particular in women, other factors 
than HF, such as comorbidities, must be sought and addressed. 
4. Women with chronic HF across the entire EF spectrum have higher NT-proBNP con-
centrations than men, but associations with patient characteristics and outcomes are 
largely similar. This supports the current use of NT-proBNP for prognostic purposes but 
the impact of the relatively large differences between sexes in the lower range warrants 
further investigation. 
The IGF-1 axis 
Mounting evidence suggests that HFpEF and HFrEF, despite similar symptoms, are 
pathophysiologically different11,15,150. However, in HFpEF, there is still a vague understanding 
of the syndrome and many areas, including when and how to treat remain elusive10. The aim 
of Study I and II was to investigate similarities and differences between HFpEF and HFrEF 
regarding metabolic biomarkers previously poorly explored in HFpEF. 
Anabolic impairment is a feature of HFrEF, but data regarding HFpEF is limited151. In Study I 
we confirmed findings in HFrEF of reduced levels of IGF-1 and the association between higher 
levels and better outcomes103,104,115. Depressed IGF-1 may merely be a marker of catabolism 
and worse HF. Still, the association was independent of HF severity. Considering the presumed 
inotropic actions of IGF-1 and role in adaptive cardiac remodeling, low IGF-1 activity may 
directly contribute to HF severity in HFrEF152,153. 
Contrary to in HFrEF, IGF-1 was no different from controls in HFpEF, and there was no asso-
ciation with outcomes. This suggests a more intact somatotropic axis in HFpEF, possibly due 
to obesity, insulin resistance, or merely absence of catabolism. Our findings were confirmed 
in a study of the multiple hormone deficiency syndrome, investigating the somatotropic, thy-
roid, adrenal, and gonadal hormonal axes154. Higher concentrations of IGF-1 were reported 
in HFpEF compared with HFrEF and overall, 46% of patients with HFpEF had no hormonal 
deficiency vs. 4% in HFrEF154. 
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Concentrations of IGFBP-1 were similarly increased in both HFpEF and HFrEF. Since 
IGFBP-1 regulates IGF-1 activity, this argues for impaired IGF-1 activity in both HF phe-
notypes, i.e. in contrast to the findings on IGF-1 itself, addressed above. Nevertheless, be-
sides regulating IGF-1, IGFBP-1 has other, independent, actions. Insulin inhibits IGFBP-1 
production, and IGFBP-1 is reduced in insulin-resistance where low levels are  associated 
with decreased NO-production, microvascular disease, and cardiovascular risk factors155,156. 
In animal models of insulin resistance, overexpression of IGFBP-1 improves insulin sen-
sitivity, lowers blood pressure, and increases vascular NO-production 157,158.  However, in 
the development of manifest T2DM, possibly due to hepatic insulin resistance, IGFBP-1 
increases159,160. High levels of IGFBP-1 are, like NPs, associated with cardiovascular mortal-
ity and predict onset HF. In sub-group analysis high IGFBP-1 levels predict HFpEF, whereas 
not clearly HFrEF111,161. 
While there was no association between IGF-1 and NT-proBNP, the association between 
IGFBP-1 and NT-proBNP was evident in both HFpEF and HFrEF. Malnutrition, cachexia, 
inflammatory cytokines, and oxidative stress all lead to increased IGFBP-1 and these factors 
are also associated with increased BNP67,162,163. Indeed, Meirovich et al. demonstrated that rat 
cardiomyocytes infused with IGFBP-1 secrete BNP163, findings that we recently have repro-
duced both in rat and human cardiomyocytes (unpublished). 
Despite the association with NT-proBNP, we found no association between high IGFBP-1 
and prognosis in neither HFpEF nor HFrEF. Considering the small sample size, this should 
be interpreted with caution. and recently, an association between high IGFBP-1 and poor 
outcome has been shown in HFrEF164. 
High NPs are risk markers in HF but simultaneously protective factors modulating adaptive 
pathways. Assuming the beneficial endothelial effects of IGFBP-1 and the strong and poten-
tially mechanistic association with BNP, possibly also IGFBP-1 participates in the adaptive 
neurohormonal activation in HF in concert with NPs. The role of IGFBP-1 in the evolution 
of and in manifest HF is nonetheless still elusive.
Leptin and adiponectin
Leptin and adiponectin concentrations are elevated in HFrEF and as a part of the obesity 
paradox, high leptin levels are associated with better outcomes in HFrEF120,124,137. In Study 
2, we show that the levels of leptin and adiponectin are similarly increased in both HFpEF 
and HFrEF. We also confirmed the obesity paradox of higher levels of leptin being associated 
with a more favourable prognosis in HFrEF. Still, the association was not independent of 
HF severity measured as NT-proBNP. This is in contrast to previous findings where leptin 
was associated with better outcomes in HFrEF independent of NT-proBNP120. However, 
adjustment for HF severity through NPs, considering the interaction between NPs and 
obesity, may not be optimal when assessing the role of leptin. Furthermore, whether leptin 
itself has a mechanistic role in the obesity paradox, through beneficial actions in manifest 
HFrEF, or is merely a bystander related to other factors in obesity, is not clear.
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In HFpEF, the obesity paradox regarding leptin could not be confirmed. The obesity 
paradox seems to be a unique feature of HFrEF, and recent data suggest, in accordance 
with our findings, that HFpEF displays a more conventional metabolic profile165. Possibly, 
hyperleptinemia in HFpEF is rather associated with the pathogenesis of the syndrome 
through the negative actions of SNS-stimulation, low-grade inflammation, oxidative stress, 
and increased aldosterone production mediated by leptin117,129. Interestingly, considering the 
sex distribution in HFpEF, women in the general population have higher concentrations of 
leptin compared with men, and leptin appears to be more strongly associated with markers of 
inflammation in women118. 
While low levels of adiponectin are associated with obesity and cardiovascular risk, 
adiponectin is increased in manifest HFrEF. Adiponectin in HF is furthermore associated 
with poor prognosis, despite its purported beneficial actions, which is sometimes referred to 
as the adiponectin paradox135-137,166. We report increased adiponectin in both HF phenotypes 
and confirm the findings of an association with poor prognosis in HFrEF135-137,167. There was 
no association in HFpEF. Again, the absence of association could be explained solely by poor 
power. However, in the development of HF, the increased risk associated with adiponectin is 
explained by the risk associated with concomitantly increased NPs168. Correspondingly, there 
was no clear association between concentrations of adiponectin and NT-proBNP in HFpEF. 
There are suggestions of adiponectin resistance in HFrEF, both in the myocardium and 
in skeletal muscle, which would be a possible explanation for the adiponectin paradox166. 
Additionally, NPs stimulate increased adiponectin release from adipose tissue and 
administration of recombinant NPs increase plasma adiponectin concentrations in HF138. 
Besides natriuresis and reverse remodeling effects, BNP also has favourable effects on lipid 
metabolism162 and these actions are possibly mediated through adiponectin169. Whether 
adiponectin is a player in the adaptive NP activation in HF, and whether it represents a 
potential treatment target remain unknown. 
Treatment targets in HF  
After decades of therapeutic success in blocking maladaptive neurohormonal activation in 
HFrEF, the discovery of adaptive pathways in HF is a new arena for therapeutic development. 
The hitherto most successful example is the combination of neprilysin inhibition and 
angiotensin receptor blockade with sacubitril-valsartan, reducing NP breakdown17. Both 
recombinant human NPs and designer peptides have been and continue to be investigated 
despite mixed success in trials64,170.  
Obesity is associated with both incident HFrEF and HFpEF and it is well established 
that obesity is associated with lower levels of NPs93,171 . The mechanism is thought to be 
both increases in neprilysin activity and expression of the NP receptor C, mediating NP 
degradation93. However, besides natriuretic and adaptive remodeling effects, NPs have 
metabolic effects such as inhibiting the proliferation of adipocytes, inducing lipolysis and 
increasing the concentrations of the cardiac energy substrate free fatty acids162,172,173. As 
mentioned, possibly, some of these effects may be mediated through adiponectin169. Both 
adiponectin and IGFBP-1 were positively associated with NT-proBNP in our studies and 
other studies show possible mechanistic links and cardioprotective effects110,157,158,163,174. 
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Hence, adiponectin and IGFBP-1 may represent potential players in the adaptive response 
in HF. An adiponectin receptor agonist, Adiporon is investigated in animal studies in various 
medical conditions, e.g. diabetic nephropathy175,176 but any role in the development of or 
manifest HF,  is not yet known. 
In HFrEF, neurohormonal antagonists are effective regardless of HF severity. In HFpEF, 
there is a hypothesis of treatment effect in mild or early stage of HFpEF, in contrast to severe 
HFpEF with potentially irreversible structural changes, different from in HFrEF. This is based 
in part on the results from I-PRESERVE and TOP-CAT with treatment effect in patients with 
less severe HF measured as lower NP-concentrations72,177. Considering the role of obesity 
and T2DM in the evolution of HFpEF through inflammation; adipokines and insulin-related 
peptides could possibly represent early treatment targets. The impressive cardiovascular 
effects of the sodium-glucose co-transporter-2 (SGLT-2) inhibitors in the treatment of 
T2DM, with reductions in HF hospitalizations of 35%, are intriguing 178,179. While these 
studies did not assess EF, HFpEF is the most prevalent type of HF in T2DM180. Although the 
early treatment effect of SGLT-2 inhibitors is likely largely related to natriuretic and diuretic 
effects, the possible roles of direct cardiac, vascular or anti-inflammatory actions are not 
fully understood. Considering the similar, but opposing actions of leptin, the hypothetical 
interaction between SGLT-2 inhibition and leptin is interesting181.
In HFrEF the obesity paradox and the role of the somatotropic axis represent possible treatment 
targets. Obesity is associated with higher concentrations of IGF-1 and IGF-1 reduces systemic 
vascular resistance and is inotropic106. Possibly, IGF-1 is one of many factors involved in the 
obesity paradox. GH therapy in HFrEF has been tested in various smaller studies with conflicting 
results. However, in GH-deficient subjects, GH replacement show promising results, stressing 
the importance of phenotyping the patients and individualizing treatment153. 
Patient reported outcomes and sex 
HF is indeed a deadly and disabling disease with significant impact on QoL affecting not only 
physical capacity, but also mental health and social life53,182. In Study III we assessed PROs 
in patients with HFpEF and potential sex differences. Ideally, HF care and therapies should 
not only improve morbidity and mortality, but also the patients’ well-being or QoL48,49. The 
importance of QoL is stressed by the fact that some patients with HF, in particular patients 
with higher NP-concentrations, more dyspnoea, and lower general QoL are even willing 
to trade life longevity for improved QoL183,184. However, this issue is complex and rather 
hypothetical. Furthermore, conflicting data has been reported, where a majority of elderly 
HF patients are unwilling to trade longevity for improved QoL. Interestingly though, female 
sex was a predictor of willingness to trade 185. In HFrEF, women also express worse QoL 
than men 50.
In Study III, women and men with stable HFpEF expressed similar disease specific QoL 
while women expressed worse general QoL than men, independent of age and HF severity. HF 
severity was adjusted for through both NYHA class and concentrations of NPs. Nevertheless, 
the adjustment for HF severity is difficult in comparisons between sexes. The perception 
of dyspnoea and NYHA class differs in women and men186, and, as we show in Study IV, 
concentrations of NT-proBNP may be higher in women. Diuretic dose is sometimes used to 
assess HF severity but considering standard dosing, lower body weight in women, and the fact 
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that women are more often prescribed diuretics this measure also has inherent difficulties7. 
Despite the severe diagnosis of HF, not even half of patients with HF rate HF as the major 
determinant of impaired QoL54. We found only weak associations of QoL with HF severity, 
and seemingly weaker in women. One explanation might be that women with HFpEF have 
more comorbidities than men8. Indeed, non-cardiovascular comorbidities, such as T2DM, 
kidney failure, and chronic obstructive pulmonary disease, may contribute even more to 
impaired functional status and QoL than HF itself or cardiovascular comorbidities in patients 
with HF187. While QoL is known to be associated with both HF severity and outcomes in both 
HFpEF and HFrEF51,188, we surprisingly only found the latter association in men. Since the 
outcome investigated was HF hospitalization or death, one explanation for the absence of 
association may be that poor QoL in women is to a larger extent explained by other factors 
than HF itself. Overall, the results suggest that patients with HFpEF, in particular women, 
have impaired QoL. To improve QoL, individual factors must be taken into account and a 
holistic approach to HF therapy and interventions is necessary. 
Natriuretic peptides and sex
There seem to be sex differences in the phenotypic expression of HF, prognosis and response 
to therapy. For multiple reasons women may be more prone to develop HFpEF compared to 
men8,189. Indeed, the biomarkers studied in this thesis exhibit sex-specific patterns118,141,190. 
In Study I and II, due to the low number of women in HFrEF, sex-specific comparisons 
between HFpEF and HFrEF were not possible and larger studies are needed to confirm and 
expand upon our findings. 
BNP or NT-proBNP is by far the most widely used biomarker in HF both for confirming 
and especially for excluding the diagnosis. It may be used as a HF severity or prognostic 
marker, potentially for guidance of therapeutic decisions,  as a therapeutic target, and as 
a surrogate endpoint in early phase trials74. As evidenced by its adaptive cardiovascular 
effects and the PARADIGM-HF trial, it also represents a therapeutic target17. In Study IV we 
show that despite higher concentrations in women across the EF spectrum, the associations 
between clinical characteristics and high NT-proBNP were largely similar in women and 
men with HF. There were only few exceptions, mainly in HFpEF. We also show that the 
prognostic ability of NT-proBNP was comparable in women and men in all EF phenotypes. 
This is in agreement with studies in acute HF13, but in contrast to reports in healthy women 
where associations with relevant comorbidities, like obesity, have a stronger effect on NP 
levels in women than in men85.  In healthy individuals, sex is an important predictor of NP-
concentrations191. Possibly, the role of sex in determining levels of NPs is “diluted” in the 
higher range of NP-s caused by HF and increased filling pressures. 
Indeed, the lower the concentrations of NPs, the more pronounced the differences in NP 
concentrations between the sexes became. In the present study, in patients with HFpEF without 
atrial fibrillation, females had 45% higher median NT-proBNP concentrations compared with 
males. In certain populations, a relatively large proportion, 30%, of patients with HFpEF have 
low or even normal NPs 192. In that context, the sexual dimorphism regarding levels of NPs 
and associations between NP-levels and comorbidities might indeed be relevant. Similarly, 
the present diagnostic cut-offs and cut-offs for inclusion in trials might yield women with less 
severe HF than men. 
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FUTURE PERSPECTIVES
HFrEF, HFpEF and HFmrEF – different challenges
HF is common, deadly, associated with poor QoL, and increasing in prevalence. However, 
the different HF phenotypes face different challenges. In HFrEF, multiple therapies exist 
but implementation of evidence based interventions and improving PRO remain a target. 
The role of the somatotropic axis, the obesity paradox, and potential sex-differences in 
pathophysiology and response to treatment are still to be elucidated. The obesity paradox and 
the somatotropic axis are, among other areas, intriguing as potential treatment targets. 
In HFpEF, there is still a vague and insufficient understanding of the syndrome, of the 
relative female predominance, and of how and when to intervene. Considering the presumed 
role of obesity and T2DM in the evolution of HFpEF and the link between the NP-system, 
metabolism, and adipose tissue, Adiponectin and IGFBP-1 may represent players in the 
adaptive response in HF. As such they warrant further investigation as potential treatment 
targets. 
HFmrEF seems to be a heterogeneous phenotype between the two extremes. To what extent 
the patients with HFmrEF are actually merely a subgroup of HFrEF, a heterogeneous mix 
of the two phenotypes, or if the pathophysiologically different phenotypes of HFrEF and 
HFpEF actually can coexist in HFmrEF is still unknown. 
Nevertheless, the one-size fits all treatment may no longer be valid for HF. Possibly 
individualized treatment is needed to improve not only survival, but also PRO. Furthermore, 
after decades of focus on blocking maladaptive response in HF, the largely unexplored 
adaptive neurohormonal activation in HF represents a vast field of potential therapeutic 
targets. And last, since women constitute 50% of the HF population, sex-specific analyses 
should be imperative and women can no longer be considered merely one subgroup of many 
in HF. 
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LIMITATIONS
A limitation in these, and in general in comparisons of HFpEF and HFrEF, is the distinct 
difference in age, sex distribution, comorbidities, and often HF severity. The three cohorts 
in Study I and II were also recruited in different settings, although they were all analysed 
consistently in the fasting state with the same, validated methods. Due to low sample size and 
few women in the HFrEF cohort, sex specific comparisons in both sexes were not possible. 
The outcome definitions in HFrEF and HFpEF furthermore differed. Hospitalization was not 
included in HFrEF due to a too high event rate, while implantation of LV assist device or heart 
transplantation were considered as deterioration in HFrEF and included in the composite 
endpoint. Though data suggests potential differences in HFpEF and HFrEF, adjustment for 
HF severity was performed, and some of the findings have been confirmed in later studies, 
we cannot rule out that our findings reflect different severities rather than differences between 
the syndromes. The interpretations of Study I and II are also limited by the small sample 
size, but being the early studies of these biomarkers in HFpEF, they could be considered 
hypothesis generating. 
The three studies in the KaRen cohort (Studies I-III) were, albeit pre-specified, retrospective 
analyses. The KaRen study was also designed before the new diagnostic criteria for HFpEF. 
Nevertheless, only 2% of the patients in the biomarker sub-study (Studies I and II) had 
EF <50% and in Study III, patients with EF <50% were excluded. In Study III, data on 
the different dimensions of MLHFQ were not available why more detailed analyses of HF 
specific QoL impairment was not possible. 
In Study IV, a cohort from SwedeHF was investigated. The inclusion criterion in SwedeHF 
is clinician-judged HF. Hence, it cannot be ruled out that some patients might not have 
HF and, considering the low awareness of HFpEF in the early study period, that HFpEF is 
underreported. SwedeHF has furthermore a relatively low coverage in primary care despite 
many HF patients are being treated there and, thus, selection bias may represent a limitation.
Although extensive adjustments were performed, we cannot exclude potential residual and 
unmeasured confounding affecting the interpretations. Cause-specific hospitalization but not 
mortality was considered due to the difficulty in assuring cause of death in registries where 
there is no adjudication of events. Finally, generalizability of our findings to other settings 
depends on similarities in population characteristics, health care organization and delivery, 
and HF management.
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CONCLUSIONS
In this analysis of metabolic hormones, NPs, PRO, and sex in HF with different EF we make 
several observations that may be relevant for understanding how metabolism, neurohormonal 
activation, and outcomes may differ according to sex and EF phenotype. 
Impairment in the IGF-1 axis is more pronounced in HFrEF compared to in HFpEF. Still, 
both EF phenotypes share increased IGFBP-1 which is associated with, and possibly 
mechanistically linked to BNP. We also found that both leptin and adiponectin were similarly 
increased in HFpEF and HFrEF. However, the obesity paradox regarding leptin was only 
demonstrated in HFrEF, pointing towards a more conventional metabolic profile in HFpEF. 
The associations between NPs and IGFBP-1 and the adipokines warrant further investigation 
considering the peptides’ potential role in the evolution of and in the adaptive response in HF. 
As in HFrEF, women with HFpEF express worse QoL than men and impaired QoL was 
associated with worse outcome in men only. Overall this suggests that, to improve QoL in 
HF patients, in particular in women, other factors than HF must be considered and addressed. 
Women with chronic, stable HF have higher NT-proBNP concentrations than men, but 
associations between NT-proBNP concentrations and clinical characteristics, as well as 
outcomes are largely similar. This supports the current use of NT-proBNP for prognostic 
purposes. Nevertheless, the impact of the relatively large differences between sexes in the 
lower range of NPs may require further investigation.
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“In the end, we’ll all become stories. Or else 
we’ll become entities. Maybe it’s the same.”
 Margaret Atwood
